Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran.
Parsian Vision Science Research Institute, Isfahan, Iran.
Acta Ophthalmol. 2019 Mar;97(2):e194-e198. doi: 10.1111/aos.13913. Epub 2018 Oct 3.
To compare topical cyclosporine-A 2% eye drop (Cs-A) with prednisolone acetate 1% eye drop for treatment of herpetic stromal keratitis (HSK).
In this randomized clinical trial, 38 eyes of 33 patients with HSK were randomly assigned to receive either 2% Cs-A or 1% prednisolone acetate eye drops. All subjects received oral acyclovir 400 mg twice a day. Slit-lamp examination, Scheimpflug tomography corneal optical densitometry (Pentacam®, Oculus Inc., Wetzlar, Germany), best-corrected visual acuity (BCVA), and intra-ocular pressure (IOP) were evaluated at the first visit, and 14 and 30 days after the treatment.
Within-group analysis revealed significant improvement of total cornea optical density after 30 days of treatment in both groups (30.3 ± 10.5 to 28.3 ± 9.8, p < 0.001 for prednisolone group, and 30.5 ± 8.8 to 28.8 ± 8.3 p < 0.001 for Cs-A group, mean ± SD). We were not able to disclose any significant difference between the two groups regarding the improvement of cornea optical density (p = 0.66). Best-corrected visual acuity (BCVA) logMAR significantly improved in both groups after 30 days of treatment (0.20 ± 0.52, p = 0.002 in prednisolone group, and 0.24 ± 0.31, p < 0.001 in Cs-A group, mean ± SD). Analysis between groups did not show a significant difference of BCVA improvement (p = 0.45). We did not observe any severe side effect attributable to drugs.
Cs-A 2% and prednisolone acetate 1% topical eye drops are effective for treatment of HSK.
比较环孢素 A 2%滴眼液(Cs-A)与醋酸泼尼松龙 1%滴眼液治疗疱疹性基质角膜炎(HSK)的疗效。
在这项随机临床试验中,33 名 HSK 患者的 38 只眼被随机分为接受 2%Cs-A 或 1%醋酸泼尼松龙滴眼液治疗。所有患者均接受阿昔洛韦 400mg,每日 2 次口服。在初次就诊时以及治疗后 14 天和 30 天进行裂隙灯检查、Scheimpflug 角膜光学密度断层扫描(Pentacam ® ,德国 Oculus 公司)、最佳矫正视力(BCVA)和眼压(IOP)检查。
两组内比较显示,治疗 30 天后总角膜光学密度均显著改善(泼尼松龙组为 30.3±10.5 至 28.3±9.8,p<0.001,Cs-A 组为 30.5±8.8 至 28.8±8.3,p<0.001)。两组间角膜光学密度改善差异无统计学意义(p=0.66)。治疗 30 天后,两组的最佳矫正视力(BCVA)logMAR 均显著改善(泼尼松龙组为 0.20±0.52,p=0.002,Cs-A 组为 0.24±0.31,p<0.001)。组间分析显示 BCVA 改善无显著差异(p=0.45)。我们未观察到任何与药物相关的严重不良反应。
Cs-A 2%和醋酸泼尼松龙 1%滴眼液滴眼均能有效治疗 HSK。